Published in Gastroenterology on June 27, 2012
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther (2014) 1.05
Clinical application of genetically modified T cells in cancer therapy. Clin Transl Immunology (2014) 1.03
Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther (2014) 0.99
Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol (2015) 0.91
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy. Oncologist (2014) 0.87
Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells. Mol Ther (2014) 0.87
Chimeric antigen receptor T-cell therapy for solid tumors. Mol Ther Oncolytics (2016) 0.86
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
First-in-man phase 1 clinical trial of gene therapy for advanced pancreatic cancer: safety, biodistribution, and preliminary clinical findings. Mol Ther (2015) 0.83
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology (2016) 0.77
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. Mol Ther (2017) 0.76
Immunotherapy in pancreatic cancer treatment: a new frontier. Therap Adv Gastroenterol (2016) 0.75
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside. Oncoimmunology (2016) 0.75
CAR's made it to the pancreas. Oncoimmunology (2012) 0.75
Efficient tumor regression by adoptively transferred CEA-specific CAR-T cells associated with symptoms of mild cytokine release syndrome. Oncoimmunology (2016) 0.75
Adoptive T-Cell Therapy for Solid Tumors. Am Soc Clin Oncol Educ Book (2017) 0.75
Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma. Front Immunol (2017) 0.75
Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity (2012) 2.80
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice. Gastroenterology (2013) 1.77
TCF/Lef1 activity controls establishment of diverse stem and progenitor cell compartments in mouse epidermis. EMBO J (2011) 1.34
IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res (2011) 1.33
CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med (2012) 1.32
Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A (2011) 1.31
Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Hepatology (2008) 1.27
Rational development of high-affinity T-cell receptor-like antibodies. Proc Natl Acad Sci U S A (2009) 1.23
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas. Proc Natl Acad Sci U S A (2008) 1.18
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol (2003) 1.17
Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferon-mediated immunity. Nat Immunol (2011) 1.14
Regression of metastatic melanoma in a patient by antibody targeting of cancer stem cells. Oncotarget (2012) 1.11
Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther (2010) 1.10
The complex role of B7 molecules in tumor immunology. Trends Mol Med (2008) 1.09
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One (2012) 1.08
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells. Prostate (2007) 1.07
Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res (2011) 1.07
Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". Mol Ther (2013) 1.05
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum Gene Ther (2010) 1.04
CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack. Cancer Res (2007) 1.04
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Effective proliferation of human regulatory T cells requires a strong costimulatory CD28 signal that cannot be substituted by IL-2. J Immunol (2007) 1.02
OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology (2012) 1.01
Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer (2011) 1.01
CD28 costimulation Impairs the efficacy of a redirected t-cell antitumor attack in the presence of regulatory t cells which can be overcome by preventing Lck activation. Mol Ther (2011) 1.00
Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle-mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response. J Bone Miner Res (2012) 0.99
The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack. Cancer Res (2010) 0.99
T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol (2007) 0.98
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells. Front Immunol (2013) 0.98
Historical biogeography and diversification of truffles in the Tuberaceae and their newly identified southern hemisphere sister lineage. PLoS One (2013) 0.98
Human CD4+ T cells lyse target cells via granzyme/perforin upon circumvention of MHC class II restriction by an antibody-like immunoreceptor. J Immunol (2006) 0.97
XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood (2006) 0.97
Reticulated acanthoma with sebaceous differentiation. Lack of association with Muir-Torre syndrome. Am J Dermatopathol (2009) 0.96
Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol (2012) 0.95
T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes. Gastroenterology (2007) 0.95
Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol (2011) 0.95
Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology (2012) 0.94
Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol (2012) 0.92
Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev (2014) 0.92
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol (2011) 0.91
CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol Immunother (2012) 0.90
Direct CD1d-mediated stimulation of APC IL-12 production and protective immune response to virus infection in vivo. J Immunol (2009) 0.90
Conditions of retinal glial and inflammatory cell activation after irradiation in a GFP-chimeric mouse model. Invest Ophthalmol Vis Sci (2010) 0.90
Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation. Hum Gene Ther (2013) 0.89
Role of the NK cell-activating receptor CRACC in periodontitis. Infect Immun (2012) 0.88
Biomechanical evaluation of classic solid and novel all-soft suture anchors for glenoid labral repair. Arthroscopy (2012) 0.88
Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis. Int J Cancer (2005) 0.87
The CD3-zeta chimeric antigen receptor overcomes TCR Hypo-responsiveness of human terminal late-stage T cells. PLoS One (2012) 0.87
A GMP-compliant protocol to expand and transfect cancer patient T cells with mRNA encoding a tumor-specific chimeric antigen receptor. Cancer Immunol Immunother (2014) 0.87
An IL12-IL2-antibody fusion protein targeting Hodgkin's lymphoma cells potentiates activation of NK and T cells for an anti-tumor attack. PLoS One (2012) 0.86
Interleukin-6 fused to an anti-idiotype antibody in a vaccine increases the specific humoral immune response against CA125+ (MUC-16) ovarian cancer. Cancer Res (2003) 0.85
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth. Oncotarget (2011) 0.85
TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther (2015) 0.85
Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy. Methods Mol Biol (2013) 0.84
Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing. Leuk Lymphoma (2013) 0.84
T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol (2010) 0.83
Costimulation tunes tumor-specific activation of redirected T cells in adoptive immunotherapy. Cancer Immunol Immunother (2006) 0.83
Of chimeric antigen receptors and antibodies: OX40 and 41BB costimulation sharpen up T cell-based immunotherapy of cancer. Immunotherapy (2013) 0.82
Survivin blockade sensitizes rhabdomyosarcoma cells for lysis by fetal acetylcholine receptor-redirected T cells. Am J Pathol (2013) 0.82
Anti-CD30-IL-12 antibody-cytokine fusion protein that induces IFN-gamma secretion of T cells and NK cell-mediated lysis of Hodgkin's lymphoma-derived tumor cells. Int J Cancer (2003) 0.82
B7/CD28 costimulation of T cells induces a distinct proteome pattern. Mol Cell Proteomics (2005) 0.82
CD7(-) T cells are late memory cells generated from CD7(+) T cells. Rejuvenation Res (2008) 0.82
Interleukin-12 antagonists as new therapeutic agents in inflammatory bowel disease. Pathobiology (2003) 0.81
Gene transfer into human cord blood-derived CD34(+) cells by adeno-associated viral vectors. Exp Hematol (2010) 0.81
Young T Cells Age During a Redirected Anti-Tumor Attack: Chimeric Antigen Receptor-Provided Dual Costimulation is Half the Battle. Front Immunol (2013) 0.81
Ultraviolet light (UV)-induced immunosuppression: is vitamin D the missing link? J Cell Biochem (2003) 0.81
Generation of activated and antigen-specific T cells with cytotoxic activity after co-culture with dendritic cells. Cancer Immunol Immunother (2001) 0.81
Infectious nickel tolerance: a reciprocal interplay of tolerogenic APCs and T suppressor cells that is driven by immunization. J Immunol (2003) 0.80
A proteomic view at T cell costimulation. PLoS One (2012) 0.80
Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy. Methods Mol Biol (2003) 0.80
Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. Int J Cancer (2004) 0.80
Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv Hematol (2011) 0.79
Targeting cancer with a bi-functional peptide: in vitro and in vivo results. In Vivo (2013) 0.78
Influencing the Wnt signaling pathway in multiple myeloma. Anticancer Res (2011) 0.77
The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy. Curr Gene Ther (2002) 0.77